Karyopharm Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-194.97	-196.04	-76.42	-143.1	-165.29	-124.09
Depreciation & Amortization	0.23	0.3	0.34	0.53	0.62	0.79
Stock-Based Compensation	13.5	14.05	18.43	21.71	35.4	29.78
Other Adjustments	26.12	78.05	-69.53	-3.28	-0.29	9.59
Change in Receivables	11.89	4.59	-3.8	20.12	-5.08	-9.62
Changes in Inventories	1.17	0.7	-1.7	1.18	-0.12	-1.46
Changes in Accounts Payable	-1.59	-1.1	1.98	0.35	1.17	-2.85
Changes in Accrued Expenses	19.22	19.06	4.2	4	-9.54	15.96
Changes in Other Operating Activities	2.97	5.02	-0.99	5.76	-6.42	-25.23
Operating Cash Flow	-59.11	-75.37	-127.49	-92.72	-149.55	-107.12
Capital Expenditures	-	-	-0.14	-	-0.12	-0.21
Purchases of Intangible Assets	-	-	-	-	-	-5.5
Purchases of Investments	-	-	-58.82	-159.15	-226.02	-45.23
Proceeds from Sale of Investments	31.29	43.38	154.44	167.09	121.88	192.78
Investing Cash Flow	31.29	43.38	95.47	7.94	-104.26	141.84
Long-Term Debt Issued	12.25	27.25	83.3	-	189.76	-
Net Long-Term Debt Issued (Repaid)	12.25	27.25	83.3	-	189.76	-
Issuance of Common Stock	50.82	9.51	1.45	1.12	3.98	13.65
Net Common Stock Issued (Repurchased)	50.82	9.51	1.45	1.12	3.98	13.65
Other Financing Activities	-7.14	-6.71	-43.11	-	-	60
Financing Cash Flow	79.85	30.05	41.65	1.12	193.74	73.65
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.02	0.02	-0.01	-0.03	-0.49	-0.05
Net Cash Flow	52.04	-1.92	9.62	-83.69	-60.56	108.32
Free Cash Flow	-59.11	-75.37	-127.63	-92.72	-149.67	-107.33
FCF Margin	-39.12%	-51.60%	-87.88%	-63.49%	-95.29%	-51.15%
Free Cash Flow Per Share	-3.95	-6.89	-15.10	-12.17	-27.42	-21.40
Levered Free Cash Flow	-160.73	-144.81	10.58	-131.27	10.07	-137.08
Unlevered Free Cash Flow	-62.22	-66.71	-115.65	-117.42	-156.29	-111.05

SEC Filings: 10-K · 10-Q